Loading...
  • PBSC
  • Evaluate the effectiveness of TXA127 in accelerating the time to initial platelet recovery following PBSC transplant with a limited number of CD34+ cells, defined as CD34+ cell concentrations ≥1.5 x 106 and ≤5.0 x 106 CD34+ cells/kg. (clinicaltrials.gov)
  • regimen
  • A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine. (highlighthealth.com)
  • The preparative regimen destroys not only the tumor cells, but it also destroys all of the normal blood making cells. (knowcancer.com)
  • The collected cells are then given back to the patient to "rescue" the patient from the devastating effects of the preparative regimen. (knowcancer.com)
  • procedure
  • In this procedure, blood is drawn from one arm, which then goes through a machine that filters out stem cells and white blood cells. (thedailystar.net)
  • After conditioning therapy, stem cells are infused into the bloodstream (usually between 30 and 60 minutes), akin to a blood transfusion procedure. (thedailystar.net)
  • A procedure in which a patient receives healthy blood-forming cells (stem cells) to replace their own stem cells that have been destroyed by disease or by the radiation or high doses of anticancer drugs that are given as part of the procedure. (cancer.gov)
  • To test a new procedure that may improve the success and decrease the side effects of stem cell transplants. (clinicaltrials.gov)
  • Participants will receive the cord blood unit as part of their stem cell transplant procedure. (clinicaltrials.gov)
  • The transplant will be performed according to the current standard of care for the procedure. (clinicaltrials.gov)
  • Given the large number of ongoing clinical trials that use systemic infusion (i.e., intravenously (IV) and intra-arterially (IA)) of MSCs expanded in vitro [ 2 , 3 ], a procedure that is minimally invasive and convenient, it is critical to understand if transplanted MSCs can home to and engraft at ischemic and injured sites in the brain to exert their therapeutic effects. (hindawi.com)
  • clinical
  • The trial was conducted at the NIH Clinical Center in Bethesda, Md., by NIH researchers at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases. (highlighthealth.com)
  • The widespread availability of clinical transplant results may help researchers recognize the limits of MHC mismatching," says Effie Wang Petersdorf, M.D., professor at the University of Washington School of Medicine and Member of the Fred Hutchinson Cancer Research Center, who leads the team of researchers and clinicians contributing transplant data to the project. (innovations-report.com)
  • This protocol allows for ongoing data collection to assess the long-term clinical and psychosocial outcomes of pediatric patients who have received a hematopoietic stem cell transplant at St. Jude Children's Research Hospital. (clinicaltrials.gov)
  • Lam is a clinical hematologist-bioengineer at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, associate professor of pediatrics at Emory University School of Medicine and a faculty member in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory. (eurekalert.org)
  • While being initially used for treatment of connective tissue disorders due to their potential to differentiate into bone, cartilage, and fat cells, the discovery that MSCs can secrete cytokines and growth factors with antiapoptotic, proangiogenic, neuroprotective, and immune-modulatory properties has sparked broad clinical interest [ 2 - 4 ]. (hindawi.com)
  • acute
  • This phase II trial studies the side effects and how well giving busulfan and etoposide followed by peripheral blood stem cell transplant (PBSCT) and low-dose aldesleukin works in treating patients with acute myeloid leukemia (AML). (clinicaltrials.gov)
  • Systemically infused mesenchymal stem cells (MSCs) are emerging therapeutics for treating stroke, acute injuries, and inflammatory diseases of the central nervous system (CNS), as well as brain tumors due to their regenerative capacity and ability to secrete trophic, immune modulatory, or other engineered therapeutic factors. (hindawi.com)
  • progenitor cells
  • Combination of both treatments synergistically increases the number of stem and progenitor cells and decreases the generation of mature myeloid progeny to enhance transplant efficiencies. (fredhutch.org)
  • In order to improve on these conditions, Dr. Dahlberg and colleagues tested whether a combination of Delta1 and SR1 generated greater numbers of stem and progenitor cells from the same original starting material. (fredhutch.org)
  • The authors suggested this was due in part to a combination of Notch blocking the formation of lymphoid progenitor cells and SR1 promoting B cell development. (fredhutch.org)
  • There were fewer stem cells and early progenitor cells. (eurekalert.org)